Dosing Schedules: Where the Confusion Starts Same medication, different intent, different dose ceilings, and different end goals
Moving from a GLP-1 agonist like semaglutide to a dual agonist like Tirzepatide can be effective, as the latter has shown greater average efficacy in studies
Patients Who've Failed Lifestyle Intervention: Sustained caloric restriction fails the majority of people who attempt it long-term not because of inadequate motivation, but because the hypothalamic weight-defense mechanisms that evolved to protect against starvation actively counteract weight loss, increasing appetite and reducing metabolic rate in response to caloric deficit
It was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) on 11 June 2026 , making it the first oral GLP-1 receptor agonist licensed for weight management in the UK
However, when choosing a flexible approach, dont overlook the importance of protein
Why Generic Fitness Apps Are Not Enough for Semaglutide Users Programming for muscle preservation during pharmaceutical weight loss is not the same as generic fat loss programming
